News - Merck Serono


Current filters:

Merck Serono

Popular Filters

19 to 43 of 69 results

Ablynx and Merck Serono expand collaboration on Nanobodies

Ablynx and Merck Serono expand collaboration on Nanobodies


Ablynx and Merck Serono have expanded their collaboration on the co-discovery and co-development of Nanobodies.

AblynxBiotechnologyEuropeImmunologicalsMerck SeronoNeurologicalOncologyResearch

Improved overall survival prompts new Phase III study for Merck Serono

Improved overall survival prompts new Phase III study for Merck Serono


Merck Serono will continue clinical development of its investigational MUC1 antigen-specific cancer immunotherapy…

BiotechnologyEuropeMerck SeronoOncologyResearch

ObsEva gets funding and makes deal with Merck Serono


Geneva, Switzerland-based ObsEva says that it has closed a 32 million Swiss franc ($34.8 million) -A…

FinancialLicensingMerck KGaAMerck SeronoObsEvaPharmaceuticalWomen's Health

Merck KGaA 2nd-qtr sales slip, but EBITDA beats forecasts


German health care and chemicals firm Merck KGaA (MRK: DE) reported second-quarter 2013 financial results,…

FinancialMerck KGaAMerck SeronoPharmaceutical

Merck Serono sets up new platform for cancer therapies innovation


Merck Serono, the biopharmaceutical division of Germany's Merck KGaA (MRK: DE) says it has created a…

BiotechnologyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Merck Serono collaborates with China's BeiGene on second-generation BRAF Inhibitor


Merck Serono, a division of Germany's Merck KGaA (MRK: DE), today (May 31) announced that it has signed…

BeiGeneBeiGene-283BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceutical

Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux


Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck KGaA…

AlchemiaBiotechnologyErbituxHA-IrinotecanMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Merck KGaA ups commitment to MS Ventures to 100 million euros


Germany's Merck KGaA says that it will increase its commitment to its strategic corporate venture capital…

BiotechnologyFinancialMerck KGaAMerck SeronoResearch

Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC


Merck Serono, a division of Germany's Merck KGaA (MRK: DE), announced detailed results from the randomized…

BiotechnologyL-BLP25Merck KGaAMerck SeronoOncologyPharmaceuticalResearchStimuvax

Merck Serono and Quintiles enter novel clinical development partnership


Merck Serono, the biotech division of Germany's Merck KGaA (MRK: DE) and Quintiles (NYSE: Q) have announced…

BiotechnologyMerck KGaAMerck SeronoPharmaceuticalQuintilesResearch

Merck KGaA adjusted 1st-qtr earnings leap 19%, beating forecasts


Shares of Germany's Merck KGaA out on 1.9% to 124.52 euros this morning (May 14), after the company reported…

FinancialMerck KGaAMerck SeronoPharmaceutical

AEterna Zentaris transfers Cetrotide rights to Merck KGaA


Canada's AEterna Zentaris (TSX: AEZ) says that its German subsidiary has entered into binding agreements…

AEterna ZentarisCetrotideLicensingMerck KGaAMerck SeronoPharmaceuticalReproductive

Merck Serono's EPP funds EspeRare Foundation, which will reposition rimeporide


Merck Serono, the biotech unit of Germany's Merck KGaA (MRK: DE) has announced the launch of the EspeRare…

BiotechnologyEspeRare FoundationFinancialMerck KGaAMerck SeronoPharmaceuticalRare diseasesResearchrimeporide

Columbia Labs extends ex-US Crinone accord with Merck Serono into 2020


USA-based Columbia Laboratories (Nasdaq: CBRX) has amended its license and supply agreement with Merck…

Columbia LaboratoriesCrinoneLicensingMerck KGaAMerck SeronoPharmaceuticalReproductive

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X


In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

Merck Serono collaborates with Nordic Bioscience for sprifermin in osteoarthritis


German drug and chemical major Merck KGaA (MRK: DE) says its Merck Serono division has entered into a…

Anti-Arthritics/RheumaticsMerck KGaAMerck SeronoNordic BiosciencePharmaceuticalResearchsprifermin

Merck KGaA posts strong sales and earnings growth for 2012


Germany's Merck KGaA today reported financial results for 2012 showing 8.7% growth in total revenues…

BiotechnologyFinancialMerck KGaAMerck SeronoPharmaceutical

Merck KGaA's glioblastoma candidate cilengitide fails in Ph III study


German drug major Merck KGaA (MRK: DE) revealed this morning that the Phase III CENTRIC trial of the…

BiotechnologycilengitideMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Merck Serono to in-license Opexa's MS drug candidate Tcelna


USA-based Opexa Therapeutics (Nasdaq: OPXA) has entered into an agreement with Merck Serono, a division…

BiotechnologyLicensingMerck KGaAMerck SeronoNeurologicalOpexa TherapeuticsPharmaceuticalTcelna

Merck Serono initiation of TH-302 Ph III trial triggers $30 million milestone for Threshold


Merck Serono, the pharma division of Germany's Merck KGaA (MRK: DE), has initiated the global Phase III…

FinancialMerck KGaAMerck SeronoOncologyPharmaceuticalResearchTH-302Threshold Pharmaceuticals

Merck Serono NSCLC vaccine candidate fails to meet primary endpoint in Ph III


Merck Serono, a division of Germany's Merck KGaA (MRK: DE), Darmstadt, says that the Phase III START…

L-BLP25Merck KGaAMerck SeronoOncologyOncothyreonPharmaceuticalResearchStimuvaxVaccines

Merck Serono collaborates with Neopharma for production in UAE


Merck Serono, a division of Germany's Merck KGaA (MRK: DE), Germany, and Unite Arab Emirates drug manufacturer…

DiabetesEuthyroxGlucophageGlucophage XRMerck KGaAMerck SeronoNeopharmaPharmaceuticalProductionRest of the WorldWomen's Health

19 to 43 of 69 results

Company Spotlight



Back to top